UA105647C2 - Арилпіперазини і їх застосування як антагоністів альфа2c - Google Patents

Арилпіперазини і їх застосування як антагоністів альфа2c

Info

Publication number
UA105647C2
UA105647C2 UAA201107596A UAA201107596A UA105647C2 UA 105647 C2 UA105647 C2 UA 105647C2 UA A201107596 A UAA201107596 A UA A201107596A UA A201107596 A UAA201107596 A UA A201107596A UA 105647 C2 UA105647 C2 UA 105647C2
Authority
UA
Ukraine
Prior art keywords
aryl piperazine
alpha2c
alpha2c antagonists
antagonists
piperazine
Prior art date
Application number
UAA201107596A
Other languages
English (en)
Russian (ru)
Inventor
Белл Девід Дін
Патрік Хольм
Арто Толванен
Герд Вольфарт
Original Assignee
Оріон Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оріон Корпорейшн filed Critical Оріон Корпорейшн
Publication of UA105647C2 publication Critical patent/UA105647C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Сполука формули (І)(I),де X, Z, А, В, D, E, R-Rі m є такими ж, як вони визначені в пунктах формули, проявляє антагоністичну активність відносно альфа2С-адренорецепторів і, таким чином, є придатною як антагоніст альфа2С-адренорецепторів.
UAA201107596A 2008-11-20 2009-11-20 Арилпіперазини і їх застосування як антагоністів альфа2c UA105647C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19335508P 2008-11-20 2008-11-20
PCT/FI2009/000097 WO2010058060A1 (en) 2008-11-20 2009-11-20 Aryl piperazine and their use as alpha2c antagonists

Publications (1)

Publication Number Publication Date
UA105647C2 true UA105647C2 (uk) 2014-06-10

Family

ID=41490335

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201107596A UA105647C2 (uk) 2008-11-20 2009-11-20 Арилпіперазини і їх застосування як антагоністів альфа2c

Country Status (21)

Country Link
US (1) US20110262352A1 (uk)
EP (1) EP2364303A1 (uk)
JP (1) JP5513515B2 (uk)
KR (1) KR20110086747A (uk)
CN (1) CN102216282A (uk)
AR (1) AR074204A1 (uk)
AU (1) AU2009317117A1 (uk)
BR (1) BRPI0921669A2 (uk)
CA (1) CA2741986A1 (uk)
CO (1) CO6382156A2 (uk)
EA (1) EA201170711A1 (uk)
GE (1) GEP20135959B (uk)
IL (1) IL212571A0 (uk)
MA (1) MA32818B1 (uk)
MX (1) MX2011005367A (uk)
NZ (1) NZ592571A (uk)
TN (1) TN2011000218A1 (uk)
TW (1) TW201024282A (uk)
UA (1) UA105647C2 (uk)
WO (1) WO2010058060A1 (uk)
ZA (1) ZA201103462B (uk)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
JOP20200052A1 (ar) * 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
PE20160842A1 (es) * 2013-12-19 2016-09-24 Bayer Pharma AG Piperidiniltetrahidroquinolinas sustituidas
CN106029657A (zh) * 2013-12-19 2016-10-12 拜耳制药股份公司 作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物
CN106029648A (zh) * 2013-12-19 2016-10-12 拜耳制药股份公司 作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物
TWI704145B (zh) * 2015-06-05 2020-09-11 芬蘭商奧利安公司 新醫藥化合物
EA201990158A1 (ru) 2016-06-29 2019-05-31 Орион Корпорейшн Производные бензодиоксана и их фармацевтическое применение
MA53711A (fr) 2018-09-25 2021-12-29 Bayer Ag Antagonistes de récepteur alpha 2-adrénergiques de sous-type c (alpha-2c) pour le traitement de l'apnée du sommeil
WO2020225188A1 (en) 2019-05-09 2020-11-12 Bayer Aktiengesellschaft COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA
EP3965766A1 (en) * 2019-05-09 2022-03-16 Bayer Aktiengesellschaft Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
CN110615774B (zh) * 2019-09-19 2022-11-11 安徽中医药大学 具有抗炎活性的苄基哌嗪类化合物、制法及医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2695295A (en) * 1952-12-19 1954-11-23 Mcneilab Inc Unsymmetrical n, n'-substituted ethylenediamine and piperazine compounds
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
JPS5515456A (en) * 1978-07-19 1980-02-02 Morishita Seiyaku Kk 2-substituted-piperazinomethyl-1,4-benzodioxane
US4788290A (en) * 1987-12-11 1988-11-29 American Home Products Corporation Serotonergic pyrazine derivatives
FI20000480A0 (fi) 2000-03-01 2000-03-01 Orion Yhtymae Oyj Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
WO2003029239A1 (en) * 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
PL372657A1 (en) 2002-04-03 2005-07-25 Orion Corporation Polycyclic compounds as potent alpha2-adrenoceptor antagonists
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
WO2004067513A1 (en) 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
TWI457122B (zh) * 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物

Also Published As

Publication number Publication date
WO2010058060A1 (en) 2010-05-27
AR074204A1 (es) 2010-12-29
NZ592571A (en) 2013-03-28
EP2364303A1 (en) 2011-09-14
BRPI0921669A2 (pt) 2018-06-26
MA32818B1 (fr) 2011-11-01
US20110262352A1 (en) 2011-10-27
AU2009317117A1 (en) 2010-05-27
JP5513515B2 (ja) 2014-06-04
CO6382156A2 (es) 2012-02-15
CN102216282A (zh) 2011-10-12
EA201170711A1 (ru) 2012-01-30
MX2011005367A (es) 2011-06-20
TN2011000218A1 (en) 2012-12-17
IL212571A0 (en) 2011-06-30
GEP20135959B (en) 2013-11-11
JP2012509302A (ja) 2012-04-19
ZA201103462B (en) 2012-01-25
KR20110086747A (ko) 2011-07-29
CA2741986A1 (en) 2010-05-27
TW201024282A (en) 2010-07-01

Similar Documents

Publication Publication Date Title
UA105647C2 (uk) Арилпіперазини і їх застосування як антагоністів альфа2c
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
MX2009009690A (es) Derivados de tiazolidina como antagonistas del receptor de orexina.
WO2008101187A3 (en) Pro-drugs of peripheral phenolic opioid antagonists
MX2010001575A (es) Derivados de 1,2-diamido-etileno como antagonistas de orexina.
MX2010002243A (es) Derivados fungicidas de 2-alquiltio-2-quinoliniloxi-acetamida.
MX2007005932A (es) 1-alquinil-2-ariloxialquilamidas y su uso como fungicidas.
UA103625C2 (en) 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides
PH12012501905A1 (en) Quinoline derivatives and their use as fungicides
TN2010000064A1 (en) Novel herbicides
GEP20156230B (en) Forms of rifaximin and usage thereof
MX341133B (es) Compuestos y metodos para la inhibición de hdac.
CO6670599A2 (es) N-(tetrazol-5-il)-y-n-(triazol-5-il)arilcarboxamidas y su uso como herbicidas
UA107791C2 (en) Pesticidal compositions
MX2010002244A (es) Nuevos fungicidas.
MY153872A (en) 2,3-dihydrobenzo{1,4} dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in treatment of peripheric and central nervous system diaseases
MX2010001364A (es) Derivados de ciclopentandiona puenteados triciclicos como herbicidas.
MX2009009774A (es) Derivados de quinolina como fungicidas.
MX2011007998A (es) Nuevos herbicidas.
MY161132A (en) Novel herbicides
PL2069332T3 (pl) Związki azetydynowe jako antagoniści receptorów oreksynowych
WO2009077471A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
MX2011007932A (es) Herbicidas nuevos.
UA102289C2 (uk) Гербіциди, одержані з циклопентадіону
UA101963C2 (en) 4-amino-pyrimidine derivatives